What's New?
 - Sitemap - Calendar
Trade Agreements - FTAA Process - Trade Issues 

espa�ol - fran�ais - portugu�s
Search

INTELLECTUAL PROPERTY RIGHTS

NATIONAL LEGISLATION - CANADA

Rules Respecting the Patent Act
JUS-96-460-01 (SOR/DORS)


Symbols to be Used for Sequence Listings Index

114. A nucleotide sequence shall be presented only by a single strand, in the 5' to 3' direction from left to right.

115. Nucleotides shall be represented using the symbols set out in the table to this section.

Table

Symbol

Meaning

Origin of designation

A

A

Adenine

G

G

Guanine

C

C

Cytosine

T

T

Thymine

U

U

Uracil

R

G or A

puRine

Y

T/U or C

pYrimidine

M

A or C

aMino

K

G or T/U

Keto

S

G or C

Strong interactions 3H-bonds

W

A or T/U

Weak interactions 2H-bonds

B

G or C or T/U

not A

D

A or G or T/U

not C

H

A or C or T/U

not G

V

A or G or C

not T, not U

N

(A or G or C or T/U) or
(unknown or other)

aNy

116. (1) Modified nucleotides shall be listed in the sequence as "N", with further information given elsewhere in the sequence listing.

(2) For the purpose of providing the further information referred to in subsection (1), the symbols set out in the table to this subsection may be used.

Table

Symbol

Meaning

ac4c

4-acetylcytidine

chm5u

5-(carboxyhydroxymethyl) uridine

cm

2'-O-methylcytidine

cmnm5s2u

5-carboxymethylaminomethyl-2-thiouridine

cmnm5u

5-carboxymethylaminomethyluridine

d

dihydrouridine

fm

2'-O-methylpseudouridine

gal q

beta, D-galactosylqueuosine

gm

2'-O-methylguanosine

i

inosine

i6a

N6-isopentenyladenosine

m1a

1-methyladenosine

m1f

1-methylpseudouridine

m1g

1-methylguanosine

m1i

1-methylinosine

m22g

2,2-dimethylguanosine

m2a

2-methyladenosine

m2g

2-methylguanosine

m3c

3-methylcytidine

m5c

5-methylcytidine

m6a

N6-methyladenosine

m7g

7-methylguanosine

mam5u

5-methylaminomethyluridine

mam5s2u

5-methoxyaminomethyl-2-thiouridine

man q

beta, D-mannosylqueuosine

mcm5s2u

5-methoxycarbonylmethyl-2-thiouridine

mcm5u

5-methoxycarbonylmethyluridine

mo5u

5-methoxyuridine

ms2i6a

2-methylthio-N6-isopentenyladenosine

ms2t6a

N-((9-beta-D-ribofuranosyl-2-methylthiopurine-6-yl) carbamoyl) threonine

mt6a

N-((9-beta-D-ribofuranosylpurine-6-yl) N-methycarbamoy1) threonine

mv

uridine-5-oxyacetic acid-methylester

o5u

uridine-5-oxyacetic acid (v)

osyw

wybutoxosine

p

pseudouridine

q

queuosine

s2c

2-thiocytidine

s2t

5-methyl-2-thiouridine

s2u

2-thiouridine

s4u

4-thiouridine

t

5-methyluridine

t6a

N-((9-beta-D-ribofuranosylpurine-6-yl) - carbamoyl) threonine

tm

2'-O-methyl-5-methyluridine

um

2'-O-methyluridine

yw

wybutosine

x

3-(3-amino-3-carboxy-propyl) uridine, (acp3) u

117. The amino acids in an amino acid sequence shall be listed in the amino to carboxy direction from left to right, and the amino and carboxy groups shall not be represented in the sequence.

118. The amino acids in an amino acid sequence shall be represented using the symbols set out in the table to this section.

Table

Symbol

Meaning

Ala

Alanine

Cys

Cysteine

Asp

Aspartic Acid

Glu

Glutamic Acid

Phe

Phenylalanine

Gly

Glycine

His

Histidine

Ile

Isoleucine

Lys

Lysine

Leu

Leucine

Met

Methionine

Asn

Asparagine

Pro

Proline

Gln

Glutamine

Arg

Arginine

Ser

Serine

Thr

Threonine

Val

Valine

Trp

Tryptophan

Tyr

Tyrosine

Asx

Aspartic or Aspartine

Glx

Glutamic or Glutamine

Xaa

D-amino acid, unknown or other

119. (1) Modified or unusual amino acids shall be listed in the sequence as "Xaa", with further information given elsewhere in the sequence listing.

(2) For the purpose of providing the further information referred to in subsection (1), the symbols set out in the table to this subsection may be used.

Table

Symbol

Meaning

Aad

2-Aminoadipic acid

bAad

3-Aminoadipic acid

bA1a

beta-Alanine, beta-Aminopropionic acid

Abu

2-Aminobutyric acid

4Abu

4-Aminobutyric acid, piperidinic acid

Acp

6-Aminocaproic acid

Ahe

2-Aminoheptanoic acid

Aib

2-Aminoisobutyric acid

bAib

3-Aminoisobutyric acid

Apm

2-Aminopimelic acid

Dbu

2,4 Diaminobutyric acid

Des

Desmosine

Dpm

2,2'-Diaminopimelic acid

Dpr

2,3-Diaminopropionic acid

EtGly

N-Ethylglycine

EtAsn

N-Ethylasparagine

Hyl

Hydroxylysine

aHyl

allo-Hydroxylysine

3Hyp

3-Hydroxyproline

4Hyp

4-Hydroxyproline

Ide

Isodesmosine

alle

allo-Isoleucine

MeGly

N-Methylglycine, sarcosine

Melle

N-Methylisoleucine

MeLys

6-N-methyllysine

MeVal

N-Methylvaline

Nva

Norvaline

Nle

Norleucine

Orn

Ornithine

 

Format to be Used for Sequence Listings Index

120. (1) The nucleotides of a nucleotide sequence shall be listed in groups of 10 bases, except in the coding parts of the sequence.

(2) Leftover bases, fewer than 10 in number at the end of non-coding parts of a sequence, shall be grouped together and separated from adjacent groups by a space.

121. The nucleotides of the coding parts of a nucleotide sequence shall be listed as triplets.

122. A nucleotide sequence shall be listed with a maximum of 16 codons or 60 nucleotides per line, with a space between each codon or group of 10 nucleotides.

123. An amino acid sequence shall be listed with a maximum of 16 amino acids per line, with a space between each amino acid.

124. (1) Amino acids corresponding to the codons in the coding parts of a nucleotide sequence shall be indicated immediately under the corresponding codons.

(2) Where a codon is split by an intron, the amino acid symbol shall be indicated below the portion of the codon containing two nucleotides.

125. (1) The nucleotides in a nucleotide sequence shall be enumerated starting at the first nucleotide of the sequence with number 1.

(2) The enumeration shall be continuous through the whole nucleotide sequence in the direction 5' to 3' and shall be marked in the right margin, next to the line containing the one-letter codes for the nucleotides, and giving the number of the last nucleotide of that line.

126. (1) Subject to subsection (2), the enumeration of amino acids in an amino acid sequence shall start at the first amino acid at the amino terminal as number 1 and shall be marked under the sequence every 5 amino acids.

(2) Where a mature protein has been identified

(a) the amino acids shall be enumerated starting at the first amino acid of the mature protein, with number 1; and

(b) the amino acids preceding the mature protein, when present, shall have negative numbers, counting backwards starting with the amino acid next to number 1.

127. (1) A sequence that is made up of one or more non-contiguous segments of a larger sequence or segments from different sequences shall be presented as a separate sequence.

(2) A sequence with a gap or gaps shall be numbered as a plurality of separate sequences with separate sequence identifier numbers.

128. The enumeration methods set out in sections 126 and 127 apply to circular nucleotide and amino acid sequences with the exception that any nucleotide or amino acid sequence may be designated by the applicant as the first nucleotide or amino acid.

129. (1) The order of presentation of the items of information in a sequence listing shall follow the order in which those items are listed in these Rules with the appropriate data element headings.

(2) The headings shall be in upper case characters.

(3) When more than one line is necessary for the text following a heading, the additional lines shall be indented to distinguish them from the heading at the left margin.

130. The sequence listing shall include, in addition to and immediately preceding the actual nucleotide or amino acid sequence, the following data element headings and the respective items of information, if applicable and when available to the applicant:

GENERAL INFORMATION

APPLICANT:

TITLE OF INVENTION:

NUMBER OF SEQUENCES:

CORRESPONDENCE ADDRESS:

COMPUTER-READABLE FORM

COMPUTER:

OPERATING SYSTEM:

SOFTWARE:

CURRENT APPLICATION DATA

APPLICATION NUMBER:

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA

APPLICATION NUMBER:

FILING DATE:

CLASSIFICATION:

PATENT AGENT INFORMATION

NAME:

REFERENCE NUMBER:

 

INFORMATION FOR SEQ ID NO.:

SEQUENCE CHARACTERISTICS

LENGTH:

TYPE:

STRANDEDNESS:

TOPOLOGY:

MOLECULE TYPE:

HYPOTHETICAL:

ANTI-SENSE:

FRAGMENT TYPE:

ORIGINAL SOURCE:

IMMEDIATE SOURCE:

POSITION IN GENOME

CHROMOSOME/SEGMENT:

MAP POSITION:

UNITS:

FEATURE

NAME/KEY:

LOCATION:

IDENTIFICATION METHOD:

OTHER INFORMATION:

PUBLICATION INFORMATION

AUTHORS:

TITLE:

JOURNAL:

VOLUME:

ISSUE:

PAGES:

DATE:

DOCUMENT NUMBER:

FILING DATE:

PUBLICATION DATE:

RELEVANT RESIDUES IN SEQ ID NO.:

SEQUENCE DESCRIPTION: SEQ ID NO.:

 

Computer-readable Form of Sequence Listings Index

131. (1) The copy of the sequence listing in computer-readable form shall comprise a printable copy of the sequence listing recorded on diskette and shall be encoded and formatted so that a printed copy of the sequence listing may be recreated using the print commands of the computer operating system configuration specified by the Commissioner in the Canadian Patent Office Record.

(2) The submitted diskette shall be write-protected.

(3) Subject to subsections (4) and (5), the diskette shall have a label permanently fixed to it that includes a description of the format of the diskette as well as the name of the applicant, the title of the invention, a reference number, the date on which the data were recorded on the diskette and the name and type of computer and operating-system that generated the file on the diskette.

(4) If all of the information referred to in subsection (3) cannot be included on a label affixed to the diskette, the label shall include the name of the applicant, the title of the invention and a reference number, and the additional information shall be provided on a container for the diskette together with the name of the applicant, the title of the invention and the reference number.

(5) If the diskette is submitted after the filing date of an application, the label shall also include the filing date of the application and information, such as the application number, sufficient to identify the application.

Continue to: Part IV: Applications filed in the period beginning on October 1, 1989 and ending on September 30, 1996